Login to Your Account


Therapies for rare diseases encouraged despite expense

By Peter Winter

Monday, March 24, 2014

It is no secret that pharmaceutical and biotech companies are beginning to invest heavily in the rare disease space. One of the attractions is that orphan drugs, developed for the treatment of rare and ultra-rare disorders, tend to be very expensive, where single patient costs can reach $350,000 and above per year.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription